Skip to main content

Soxataltinib, a highly selective CNS-penetrant RET inhibitor demonstrates durable activity in RET fusion-positive non-small cell lung cancer phase 2 study

In brief

Soxataltinib produces tumor responses in 85% of RET fusion-positive lung cancer patients

In a single-arm phase 2 study, 85% of patients with advanced RET fusion-positive lung cancer had a tumor response; median time before disease progression was not reached after 19.3 months of follow-up. Brain tumor responses were seen too, but in only nine patients with measurable brain disease, and severe treatment-related side effects were common, so larger studies must confirm the benefit and risks.

Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (Q1)
Published
5 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Anwen Xiong, Xiangjiao Meng, Xingya Li, Yongchang Zhang, Nong Yang, Qitao Yu, et al.
PMID
42988049
DOI
10.1016/j.jtho.2026.106244

Why clinicians should know about it

Abstract

Selective RET inhibitors have transformed the treatment landscape of RET fusion-positive non-small cell lung cancer (NSCLC), yet durable systemic and intracranial disease control remains a major clinical challenge. We conducted a multicenter, single-arm phase 2 study of soxataltinib, a highly selective CNS-penetrant RET inhibitor, in treatment-naïve (n=56) and previously treated patients (n=49) with advanced RET fusion-positive NSCLC. At a median follow-up of 19.3 months, the independent review committee (IRC)-assessed ORR was 84.8% (95% CI, 76.4-91.0), including 89.3% in treatment-naïve and 79.6% in previously treated patients. Responses were observed across clinically relevant subgroups, including patients with baseline brain metastases. Median progression-free survival (PFS) was not reached in the overall population. Intracranial response was observed in patients with measurable CNS disease [ intracranial ORRs were 100% (4/4) in treatment-naïve and 60.0% (3/5) in previously treated patients], supporting clinically meaningful CNS control. Grade ≥3 TRAEs occurred in 76.2% of patients and were generally manageable with dose modification; treatment discontinuation due to adverse events occurred in 1.9%, with no treatment-related deaths. Soxataltinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC, supporting its further development as a next-generation RET-targeted therapy.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.